6 terminated, 1 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 6, Completed 1 |
Follow fulranumab: new trials by email Literature Review of fulranumab trials Research Report on fulranumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis Oxycodone CR (standard pain medication), JNJ-42160443, Placebo - Osteoarthritis, Osteoarthritis, Knee | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 196 | 2010-04-20 | 2020-03-11 |
| A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain Placebo, JNJ-42160443 - Cystitis, Interstitial, Urologic Diseases | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 31 | 2010-04-06 | 2021-10-18 |
| A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg) - Diabetic Neuropathy | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 77 | 2009-11-01 | 2016-06-03 |
| A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain JNJ-42160443, Placebo - Pain, Burning, Pain, Crushing | Phase 2 | Completed | Janssen Research & Development, LLC | 100 | 2009-10-01 | 2016-01-22 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain JNJ-42160443, Placebo - Osteoarthritis, Osteoarthritis, Hip | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 467 | 2009-09-16 | 2020-03-11 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) JNJ-42160443, Placebo - Pain, Neuralgia, Postherpetic | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 112 | 2009-09-01 | 2016-05-02 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg - Low Back Pain, Low Back Pain, Recurrent | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 389 | 2009-09-01 | 2016-06-06 |
Pain (5) · Arthralgia (2) · Neuralgia (2) · Osteoarthritis (2) · Osteoarthritis, Knee (2) · Cancer Pain (1) · Chronic Pain (1) · Cystitis (1) · Cystitis, Interstitial (1) · Diabetic Neuropathies (1) · Low Back Pain (1) · Mononeuropathies (1) · Neuralgia, Postherpetic (1) · Osteoarthritis, Hip (1) · Urinary Bladder Diseases (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Janssen Research & Development, LLC (1)
United States (7) · Canada (4) · Belgium (2) · Netherlands (2) · Poland (2) · Spain (2) · France (1) · Portugal (1) · South Korea (1)
PMID 27101815, PMID 27153360, PMID 27238963, PMID 27748055, PMID 28056917, PMID 32734597
2009 (4), 2008 (3)